Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine. Issue 4 (11th April 2019) - Rosen, Noah; Pearlman, Eric; Ruff, Dustin; Day, Kathleen; Nagy, Abraham Jim